Antibody News You Should Know - The Antibody Society

Antibody-based therapeutics are advancing in clinical development at a rapid rate and being approved in record numbers.

To keep our members up to date on recent events, we compile relevant information from news releases and other sources, and send this “Antibody News You Should Know” to our members via email twice per month. We include news about:

Clinical studies started recently, focusing on the first Phase 1, Phase 2 or Phase 3 study
Submission of marketing applications
Marketing approvals
Licensing deals
Regulatory agency designations granted (e.g., Orphan Drug, PRIME, Breakthrough Therapy, Priority review)

As of March 15, 2020, we are featuring in-depth coverage of news related to COVID-19 biologic interventions.

As a service to the community, The Antibody Society offers access to past “Antibody News You Should Know”, which can be accessed via links below. “Antibody News” have also been compiled into PDFs for convenience. The PDFs, which can be downloaded via links below, include links to the original source and can be searched by keywords (e.g., SARS-CoV-2, bispecific, antibody-drug conjugate).